Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford Biomedica Receives European Orphan Drug Designation For Ushstat
UshStat is designed to deliver a corrected version of the MYO7A gene into the cells of the retina, using the company’s LentiVector gene delivery technology. In collaboration with
UshStat is designed to deliver a corrected version of the MYO7A gene into the cells of the retina, using the company’s LentiVector gene delivery technology. In collaboration with
Victoza is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan.It is indicated as monotherapy or as an add-on to sulphonylurea (SU) in
CHK1 is a key component of a biochemical pathway responsible for reducing the effectiveness of traditional cancer therapeutics such as chemotherapy. The collaboration has developed novel, potent and
ValiRx is heading the consortium to take the company’s lead GeneICE product toward human trials and commercialisation. GeneICE compounds are based on proprietary technology, designed for the long-term
Lupin’s Memantine HCL tablets are AB-rated to Namenda tablets, indicated for the treatment of modrate to severe dementia of alzheimer’s type. Vinita Gupta, group president and CEO of
SafeBridge conducted a 60-element review of AMRI programs, procedures and facilities used for the containment and control of potent APIs. Based on the quantitative results of the Potent
The company said that in the ensuing seven months, it made enhancements and took appropriate corrective actions. The facility was reinspected in November 2009 and was found to
The approval of Aloxi is based on the compelling results of a large multicenter randomized double-blind clinical trial (Protect study) conducted in Japan, which demonstrated the superiority of
LX4211, dosed as a single agent, provided improvements in glycemic control, demonstrating benefits in the primary and multiple secondary efficacy endpoints. The recently completed study was a four-week,
Hydrochlorothiazide capsules 12.5mg is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Each capsule contains the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose